Contra-indicated in suicidal or untreated/inadequately treated depression, in hepatic impairment. or in patients taking MAO inhibitors, reserpine or tetrabenazine.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Austedo (Teva)
- INDICATIONS: Chorea associated with Huntington's disease
- CLASS: Vesicular monoamine transporter 2 inhibitor
- HALF-LIFE: 9–10 hours
- FDA APPROVAL DATE: 04/03/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol or other sedating drugs, Bupropion, Dopamine antagonists or antipsychotics, Fluoxetine, MAO inhibitors, Paroxetine Hydrochloride, Quinidine, Strong CYP2D6 inhibitors, Tetrabenazine - PREGNANCY: Based on animal data, may cause fetal harm
DEPRESSION AND SUICIDALITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 04/02/2024
